摘要
为了评价美罗华与CHOP联合治疗B细胞性非霍奇金淋巴瘤(non-Hodgkin’s lymphoma,NHL)的临床效果及不良反应,用同期对照的前瞻性研究方法,将22例B细胞性NHL患者分为研究组(美罗华组)和对照组,研究组11例用CHOP方案(环磷酰胺、多柔比星、长春新碱和泼尼松)联合美罗华治疗;对照组11例单用CHOP方案。结果美罗华组完全缓解率(CR)达72.7%(8/11),总有效率90.9%(10/11);对照组CR为36.4%(4/11),总有效率为54.6%(6/11),两组疗效差异有统计学意义,P=0.0018。初步研究结果提示,美罗华联合CHOP方案治疗CD20阳性的B细胞性NHL的疗效显著,不良反应与单纯化疗相似,可作为该病目前的首选方案。
The objective of study was to evaluate the therapeutic effects and side-effects of Rituximab combined with CHOP in treatment of B cell non-Hodgkin＇s lymphoma. A prospective study with concurrent control group was carried out. Twenty-two cases of B cell non-Hodgkin＇s lymphoma were divided into 2 groups. The 11 cases in research group （Rituximab group） were administered by Rituximab combined with CHOP （cyclophosphamide,doxorubicin,vincristine,and prednisone） regimen. The remaining 11 cases in the control group were treated with CHOP regimen only. The complete remission （CR） rate and total response rate in Rituximab group were 72.7%0 （8/11） and 90.9g （10/11） respectively, while those corresponding rates in the control group were 36.40/00 （4/11） and 54.60/00 （6/11 ）, respectively. The therapeutic differences between the two groups showed a statistical significance, P= 0. 001 8. In conclusion, compared with CHOP regimen chemotherapy, Rituximab combined CHOP regimen shows higher therapeutic effects. The side-effects in the Rituximab group are the same as those in the control group. Rituximab combined CHOP regimen can be the first choice in the treatment of B cell Non-Hodgkin＇s lymphoma.
出处
《中华肿瘤防治杂志》
CAS
2007年第20期1589-1590,共2页
Chinese Journal of Cancer Prevention and Treatment
